Browse
Submit Data
Databases
API
Help

Dataset Information

505 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Quantitative Analysis of the erythrocyte membrane proteins in polycythemia vera patients treated with hydroxycarbamide

ABSTRACT: Polycythemia vera (PV) is a myeloproliferative disorder arising in pluripotent stem cells that causes an abnormal erythrocyte mass. More than 90% of PV patients have a mutation in JAK2 protein that is closely associated with the erythrocyte membrane. We report findings on quantitative analysis of the erythrocyte membrane proteins differentially regulated in PV patients treated with hydroxycarbamide.
Kottahachchi et al., EuPA Open Proteomics 7, 43-53
Quantitative analysis of the erythrocyte membrane proteins in polycythemia vera patients treated with hydroxycarbamide
DOI:10.1016/j.euprot.2015.04.001
http://www.sciencedirect.com/science/article/pii/S2212968515000100

INSTRUMENT(S): QSTAR, Q Exactive

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Erythrocyte

SUBMITTER: Susumu Imanishi

LAB HEAD: Garry L. Corthals

PROVIDER: PXD001532 | Pride | 2015-05-11

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Similar Datasets

Proteome in human hematopoietic stem and progenitor cell subpopulations from polycythemia vera patients and controls

Project description:Polycythemia vera (PV) is a myeloproliferative neoplasm (MPN) characterized by hyper-proliferation of the erythroid, megakaryocytic and granulocytic lineages and the presence of an activating mutation in JAK2. To elucidate mechanisms that regulate PV stem cells, we applied a newly developed data-independent acquisition (DIA) mass spectrometry (MS) technology to purified hematopoietic stem and progenitor cell (HSPC) subpopulations of patients with chronic and progressed PV. Proteomic analyses were supplemented by RNA-sequencing (RNA-seq) and identified targets validated by flow cytometry and functional in vitro assays.

2022-01-19 | PXD021178 | Pride

Gene expression data from CD34+ BMMCs/PBMCs from JAK2V617F positive and CALR mutated MPN patients

2018-10-29 | GSE120362 | GEO

RNA-seq in different hematopoietic stem and progenitor cell subpopulations of patients with chronic and progressed polycythemia vera and controls

Project description:Hematopoietic stem/multipotent progenitor cells (HSC/MPPs, referred to as HSCs) can differentiate into functionally divergent cell lineages including common myeloid progenitors (CMPs), megakaryocyte-erythrocyte progenitors (MEPs) or granulocyte-macrophage progenitors (GMPs). When this stem cell differentiation process is altered, abnormal (pre)leukemic stem cell subpopulations may form, eventually resulting in clonal hematopoiesis and in the onset of chronic or acute leukemias such as for example polycythemia vera (PV) or acute myeloid leukemia (AML). To understand the molecular and biochemical changes underlying trilineage hyperproliferation in PV and the process of progression to post-PV myelofibroses (post-PV MF) or post-PV acute myeloid leukemia (post-PV AML), highly refined analyses of PV stem and progenitor cells are required. We performed transcriptomics and proteomics analyses in hematopoietic stem and progenitor cells of patients with chronic and progressed PV as well as controls to identify key molecular changes in these cell subpopulations for disease manifestation and progression.

2021-04-22 | GSE145802 | GEO

Gene expression data from CD34+ BMMCs/PBMCs from MPN patients vs. healthy controls

Project description:Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) consist of primary myelofibrosis (PMF), polycythemia vera (PV), essential thrombocythemia (ET) and seconday myelofibrosis (SMF), comprising post-ET-MF(pET-MF) and post-PV-MF(pPV-MF). In this dataset, we compare the gene expression data of bone marrow or peripheral blood mononuclear cells (BMMCs/PBMCs) of CD34+ cells from MPN patients and healthy donors.

2021-11-24 | GSE174060 | GEO

Differential gene expression profiles of human promyelocytic leukemia cell lines exposed to benzene and its metabolites

Project description:The gene expression profiles of HL-60 cells were determined with IC50 doses of 3 chemicals (benzene, hydroquinone and benzoquinone) at a 3 h time point. Assays were performed in triplicate for each chemical/dose, and individual gene-expression profiles were determined for each chemical at the tested concentration doses. SUBMITTER_CITATION: http://www.sciencedirect.com/science/article/pii/S1382668911001049, DOI: doi:10.1016/j.etap.2011.06.001, Reference: ENVTOX 1446

2010-07-24 | GSE23018 | GEO

Transcriptome analysis of JAK2V617F HSPC and endogenous HSPC from irradiated and non-irradiated legs of recipient mice transplanted with JAK2V617F hematopoietic cells

Project description:using transplantation of transgenic knock-in JAK2V617F hematopoietic cells into a single irradiated leg, we show development of Polycythemia Vera (PV) from a single anatomical site in immuno-competent mice. Mutant cells colonizing the non-irradiated leg efficiently induce PV. We compared transcriptomic profiles of sorted JAK2V617F HSPC and their reciprocal endogenous WT HSPC in the non-irradiated and irradiated legs from recipient mice transplanted with JAK2V617F hematopoietic cells.

2022-03-01 | GSE165902 | GEO

Changes of miRNA expression in granulocytes of patients with polycythemia vera (PV) and essential thrombocythemia (ET) receiving INCB018424 in a Phase 2 study

Project description:A global microRNA expression profile was obtained from gradient-purified granulocytes (>95% pure) collected at the time of screening and at cycle 4 of treatment Protocol #18424-256 is a Phase 2 study of the JAK1 and JAK2 inhibitor INCB01842 in patients with advanced polycythemia vera (PV) and essential thrombocythemia (ET) refractory to hydroxyurea;

2012-09-26 | GSE32194 | GEO

Gene expression data from CD34+ BMMCs/PBMCs from JAK2V617F positive MPN patients vs. Healthy controls

Project description:Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) consist of primary myelofibrosis (PMF), polycythemia vera (PV), essential thrombocythemia (ET) and seconday myelofibrosis (pPV-MF or pET-MF) In this dataset, we compare the gene expression data of bone marrow (BM) or peripheral blood (PB) mononuclear cells of CD34+ cells from JAK2V617F mutated patients vs. healthy donors

2022-08-26 | GSE136335 | GEO

Bone marrow erythroblast arrays

Project description:JAK2V617F mutation is found in most patients with a myeloproliferative neoplasm (MPN), including polycythemia vera (PV), essential thrombocythemia (ET). We have demonstrated that heterozygous human JAK2V617F are associated with ET-like phenotypes while homozygosity for human JAK2V617F results in a striking phenotypic switch from an ET-like to PV-like phenotype. The resultant erythrocytosis is driven by increased numbers of erythroid progenitors and enhanced erythroblast proliferation. To establish the molecular mechanisms and pathways involved in the erythrocytosis, microarray was performed on bone marrow erythroblasts isolated from 8-10 weeks old homozygous, heterozygous mice and wildtype controls (3 mice for each genotype).

2014-03-26 | E-MTAB-2427 | biostudies-arrayexpress

Transcriptional profiling of normal and JAK2V617F-positive erythroblasts of polycythemia vera and essential thrombocythemia

Project description:This experiment was designed to identify genes differentially expressed in association with the JAK2V617F mutation in polycythemia vera (PV) and essential thrombocythemia (ET). Peripheral blood was obtained from 20 ET and 16 PV patients and erythroid progenitors were grown in semi-solid methylcellulose media supplemented with 0.01 U/ml erythropoietin. Individual clones were plucked and genotyped for the presence of the JAK2V617F mutation, and up to 20 normal and mutant colonies were pooled from each patient, and subjected to expression profiling. In total, 72 expression profiling datasets were generated, representing paired samples of normal and mutant cells from 36 patients.

2011-11-22 | E-MTAB-384 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data